Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Net Asset Quality Index
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Net Asset Quality Index of 94.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.89 Billion minus total liabilities of CN¥161.98 Million yields net assets of CN¥2.73 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300357 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2009–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the index stands at 94.4%, representing net assets of CN¥2.73 Billion against total assets of CN¥2.89 Billion CNY. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.8% | CN¥2.46 Billion | CN¥2.71 Billion | CN¥250.30 Million | ▲ +0.8 pp |
| 2023 | 89.9% | CN¥2.30 Billion | CN¥2.56 Billion | CN¥258.46 Million | ▼ -2.3 pp |
| 2022 | 92.2% | CN¥2.03 Billion | CN¥2.20 Billion | CN¥170.76 Million | ▼ -0.8 pp |
| 2021 | 93.0% | CN¥1.80 Billion | CN¥1.93 Billion | CN¥135.36 Million | ▼ -2.2 pp |
| 2020 | 95.2% | CN¥1.53 Billion | CN¥1.60 Billion | CN¥76.61 Million | ▲ +0.6 pp |
| 2019 | 94.7% | CN¥1.35 Billion | CN¥1.43 Billion | CN¥76.25 Million | ▲ +0.6 pp |
| 2018 | 94.1% | CN¥995.42 Million | CN¥1.06 Billion | CN¥62.47 Million | ▼ -0.4 pp |
| 2017 | 94.5% | CN¥801.26 Million | CN¥848.31 Million | CN¥47.05 Million | ▲ +0.4 pp |
| 2016 | 94.1% | CN¥655.58 Million | CN¥696.89 Million | CN¥41.32 Million | ▼ -1.3 pp |
| 2015 | 95.3% | CN¥582.91 Million | CN¥611.49 Million | CN¥28.57 Million | ▼ -1.3 pp |
| 2014 | 96.7% | CN¥513.55 Million | CN¥531.31 Million | CN¥17.75 Million | ▲ +1.2 pp |
| 2013 | 95.4% | CN¥251.92 Million | CN¥263.95 Million | CN¥12.04 Million | ▲ +0.5 pp |
| 2012 | 94.9% | CN¥181.38 Million | CN¥191.11 Million | CN¥9.73 Million | ▲ +8.2 pp |
| 2011 | 86.7% | CN¥127.61 Million | CN¥147.19 Million | CN¥19.58 Million | ▲ +4.9 pp |
| 2010 | 81.8% | CN¥90.44 Million | CN¥110.52 Million | CN¥20.08 Million | ▼ -10.3 pp |
| 2009 | 92.2% | CN¥111.89 Million | CN¥121.38 Million | CN¥9.49 Million | — |